WO2022173058A1 - 三次元組織体の製造方法及び脂肪由来幹細胞の分化促進方法 - Google Patents
三次元組織体の製造方法及び脂肪由来幹細胞の分化促進方法 Download PDFInfo
- Publication number
- WO2022173058A1 WO2022173058A1 PCT/JP2022/005969 JP2022005969W WO2022173058A1 WO 2022173058 A1 WO2022173058 A1 WO 2022173058A1 JP 2022005969 W JP2022005969 W JP 2022005969W WO 2022173058 A1 WO2022173058 A1 WO 2022173058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- acid
- extracellular matrix
- adipose
- stem cells
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 78
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 62
- 230000004069 differentiation Effects 0.000 title claims description 55
- 230000001737 promoting effect Effects 0.000 title claims description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 183
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 53
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 claims abstract description 52
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 52
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims abstract description 52
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 52
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims abstract description 52
- PAHGJZDQXIOYTH-UHFFFAOYSA-N pristanic acid Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C(O)=O PAHGJZDQXIOYTH-UHFFFAOYSA-N 0.000 claims abstract description 47
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 27
- 229930195729 fatty acid Natural products 0.000 claims abstract description 27
- 239000000194 fatty acid Substances 0.000 claims abstract description 27
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 27
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 claims abstract description 26
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 26
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 26
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 claims abstract description 26
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 26
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000005642 Oleic acid Substances 0.000 claims abstract description 26
- 235000021319 Palmitoleic acid Nutrition 0.000 claims abstract description 26
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims abstract description 26
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims abstract description 24
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims abstract description 24
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims abstract description 24
- 210000001519 tissue Anatomy 0.000 claims description 176
- 210000002744 extracellular matrix Anatomy 0.000 claims description 175
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 174
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 174
- 239000002609 medium Substances 0.000 claims description 116
- 102000008186 Collagen Human genes 0.000 claims description 98
- 108010035532 Collagen Proteins 0.000 claims description 98
- 229920001436 collagen Polymers 0.000 claims description 98
- 239000003112 inhibitor Substances 0.000 claims description 82
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 70
- 238000011534 incubation Methods 0.000 claims description 39
- 239000012736 aqueous medium Substances 0.000 claims description 35
- 241000283690 Bos taurus Species 0.000 claims description 19
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 claims 10
- 239000000306 component Substances 0.000 description 216
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 60
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 39
- 150000002632 lipids Chemical class 0.000 description 26
- 238000004132 cross linking Methods 0.000 description 24
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 24
- 238000010186 staining Methods 0.000 description 19
- 210000004204 blood vessel Anatomy 0.000 description 17
- 238000010899 nucleation Methods 0.000 description 13
- 108010049003 Fibrinogen Proteins 0.000 description 12
- 102000008946 Fibrinogen Human genes 0.000 description 12
- 229940012952 fibrinogen Drugs 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000010867 Hoechst staining Methods 0.000 description 8
- 108090000190 Thrombin Proteins 0.000 description 8
- 102000013373 fibrillar collagen Human genes 0.000 description 8
- 108060002894 fibrillar collagen Proteins 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000011759 adipose tissue development Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012758 nuclear staining Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 102100034134 Activin receptor type-1B Human genes 0.000 description 2
- 102100034135 Activin receptor type-1C Human genes 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 239000012571 GlutaMAX medium Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 2
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010002466 Non-Fibrillar Collagens Proteins 0.000 description 2
- 102000000641 Non-Fibrillar Collagens Human genes 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 210000001648 gingival epithelial cell Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FJCDSQATIJKQKA-UHFFFAOYSA-N 2-fluoro-n-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C2=C(N=C(CNC=3C(=CC=CC=3)F)N2)C2=CN3N=CN=C3C=C2)=N1 FJCDSQATIJKQKA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000001406 Perilipin Human genes 0.000 description 1
- 108060006002 Perilipin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- -1 carbodiimide sulfonate Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 208000035736 spondylodysplastic type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Definitions
- the present invention relates to a method for producing a three-dimensional tissue and a method for promoting differentiation of adipose-derived stem cells.
- a three-dimensional tissue is formed by arranging cells coated with a film containing collagen three-dimensionally to form a three-dimensional tissue.
- Patent Document 1 comprising mixing cells with a cationic substance and an extracellular matrix component to obtain a mixture, collecting cells from the obtained mixture, and forming cell aggregates on a substrate.
- Patent Document 2 A method for producing a three-dimensional cell tissue (Patent Document 2) is known.
- Patent Document 3 the present inventors have found a method for producing a large-sized three-dimensional tissue with a thickness of 1 mm or more with a relatively small number of cells by contacting cells with fragmented exogenous collagen
- a three-dimensional tissue which is an aggregate of cells artificially produced by cell culture.
- three-dimensional tissues containing adipocytes are expected to be used as substitutes for experimental animals, transplant materials, etc.
- differentiation of adipose-derived stem cells is expected.
- a method to facilitate is desired.
- the present invention has been made in view of the above circumstances, and aims to provide a method for promoting the differentiation of adipose-derived stem cells into mature adipocytes in the production of three-dimensional tissues containing mature adipocytes.
- the present inventors have found that incubation of adipose-derived stem cells in the presence of a TGF ⁇ type I receptor inhibitor and/or a specific fatty acid promotes the differentiation of adipose-derived stem cells into mature adipocytes. The inventors have found that it is possible to do so, and have completed the present invention.
- the present invention includes, for example, the following inventions.
- [1] Incubating cells containing at least adipose-derived stem cells in the presence of one or more fatty acids selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.
- a method for producing a three-dimensional tissue containing mature adipocytes comprising: [2] The production method of [1], which comprises incubating the cells in the presence of a TGF ⁇ type I receptor inhibitor.
- Incubating in the presence of the TGF ⁇ type I receptor inhibitor means incubating in a medium containing the TGF ⁇ type I receptor inhibitor, and the content of the TGF ⁇ type I receptor inhibitor in the medium is 1 ⁇ M or more and 10 ⁇ M or less, the manufacturing method according to [2].
- [5] The production method according to any one of [1] to [4], wherein the adipose-derived stem cells are bovine-derived.
- [6] The production method according to any one of [1] to [5], wherein the incubation is performed for 96 hours or more and 384 hours or less.
- a method for promoting differentiation of adipose-derived stem cells comprising: [12] The method of [11], comprising incubating the cells in the presence of a TGF ⁇ type I receptor inhibitor.
- Incubating in the presence of the TGF ⁇ type I receptor inhibitor means incubating in a medium containing the TGF ⁇ type I receptor inhibitor, and the content of the TGF ⁇ type I receptor inhibitor in the medium is 1 ⁇ M or more and 10 ⁇ M or less.
- [16] The method of any one of [11]-[15], which comprises incubating the cells comprising at least adipose-derived stem cells with the fragmented extracellular matrix component in the presence of a TGF ⁇ type I receptor inhibitor.
- [17] The method of [16], wherein the fragmented extracellular matrix component is a fragmented collagen component.
- [P1] A method for producing a three-dimensional tissue containing mature adipocytes, comprising incubating cells containing at least adipose-derived stem cells in the presence of a TGF ⁇ type I receptor inhibitor.
- [P2] [P1 ] The manufacturing method as described in. [P3] The method of [P1] or [P2], wherein the cells containing at least adipose-derived stem cells do not contain mature adipocytes.
- Incubating in the presence of the TGF ⁇ type I receptor inhibitor means incubating in a medium containing the TGF ⁇ type I receptor inhibitor, and the content of the TGF ⁇ type I receptor inhibitor in the medium is 1 ⁇ M or more and 10 ⁇ M or less, the production method according to any one of [P1] to [P3].
- [P5] The production method according to any one of [P1] to [P4], wherein the adipose-derived stem cells are bovine-derived.
- [P6] The production method according to any one of [P1] to [P5], wherein the incubation is performed for 96 hours or more and 384 hours or less.
- [P7] The production method according to any one of [P1] to [P6], which comprises incubating the cell with the fragmented extracellular matrix component in the presence of a TGF ⁇ type I receptor inhibitor.
- [P8] The production method according to [P7], wherein in the three-dimensional tissue, the fragmented extracellular matrix component is arranged in the interstices between the cells.
- [P9] The production method of [P7] or [P8], wherein the fragmented extracellular matrix component is a fragmented collagen component.
- [P10] The production method according to any one of [P7] to [P9], further comprising the step of contacting the cells with the fragmented extracellular matrix component in an aqueous medium before incubation.
- [P11] A method for promoting differentiation of adipose-derived stem cells, comprising incubating cells containing at least adipose-derived stem cells in the presence of a TGF ⁇ type I receptor inhibitor.
- Incubating in the presence of the TGF ⁇ type I receptor inhibitor means incubating in a medium containing the TGF ⁇ type I receptor inhibitor, and the content of the TGF ⁇ type I receptor inhibitor in the medium is 1 ⁇ M or more and 10 ⁇ M or less, the method according to [P11].
- [P13] The method of [P11] or [P12], wherein the adipose-derived stem cells are bovine-derived.
- [P14] The method according to any one of [P11] to [P13], wherein the incubation is performed for 96 hours or more and 384 hours or less.
- [P15] The method of any one of [P11] to [P14], which comprises incubating the cells comprising at least adipose-derived stem cells with the fragmented extracellular matrix component in the presence of a TGF ⁇ type I receptor inhibitor.
- [P16] The method of [P15], wherein the fragmented extracellular matrix component is a fragmented collagen component.
- [P17] The method of [P15] or [P16], further comprising contacting the cells with the fragmented extracellular matrix component in an aqueous medium prior to incubation.
- [P18] A method for promoting differentiation of adipose-derived stem cells, comprising incubating cells containing at least adipose-derived stem cells in the presence of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.
- [P19] The method of [P18], wherein the adipose-derived stem cells are bovine-derived.
- [P20] The method of [P18] or [P19], wherein the incubation is performed for 96 hours or more and 384 hours or less.
- [P21] [ P18] to [P20].
- [P22] The method of [P21], wherein the fragmented extracellular matrix component is a fragmented collagen component.
- [P23] The method of [P21] or [P22], further comprising contacting the cells with the fragmented extracellular matrix component in an aqueous medium prior to incubation.
- the differentiation of adipose-derived stem cells into mature adipocytes is promoted.
- By promoting differentiation into mature adipocytes it becomes possible to produce a three-dimensional tissue containing mature adipocytes in a short period of time.
- FIG. 1 is a graph showing the results of comparing the fluorescence intensity of lipid staining with Nile Red of the three-dimensional tissue prepared in Production Example 1 (*p ⁇ 0.05, **p ⁇ 0.01, ** *p ⁇ 0.001).
- FIG. 2 is a graph showing the results of comparing the fluorescence intensity of lipid staining with Nile Red in the three-dimensional tissue produced in Production Example 2 (*p ⁇ 0.05, **p ⁇ 0.01).
- 3 shows the results of lipid staining with Nile Red of the three-dimensional tissue produced in Production Example 3.
- FIG. White dots indicate nuclei (Hoechst staining).
- FIG. 4 is a graph showing the results of comparison of the fluorescence intensity increase rate of lipid staining with Nile Red for the three-dimensional tissue produced in Production Example 3.
- FIG. 4 is a graph showing the results of comparison of the fluorescence intensity increase rate of lipid staining with Nile Red for the three-dimensional tissue produced in Production Example 3.
- FIG. 5 shows the results of lipid staining of the three-dimensional tissue produced in Production Example 4 with Nile Red.
- White dots indicate nuclei (Hoechst staining).
- FIG. 6 is a graph showing the results of comparison of the fluorescence intensity increase rate of lipid staining with Nile Red for the three-dimensional tissue produced in Production Example 4.
- FIG. 7 is a graph showing the results of comparison of fluorescence intensity of lipid staining with Nile red of the three-dimensional tissue on day 3, day 7, and day 14 of differentiation in Production Example 5.
- FIG. 8 shows the results of lipid staining with Nile red of the three-dimensional tissue on day 3 of differentiation in Production Example 5.
- FIG. White dots indicate nuclei (Hoechst staining).
- FIG. 9 shows the results of lipid staining with Nile red of the three-dimensional tissue on day 7 of differentiation in Production Example 5.
- FIG. White dots indicate nuclei (Hoechst staining).
- 10 shows the results of lipid staining with Nile red of the three-dimensional tissue on day 14 of differentiation in Production Example 5.
- FIG. White dots indicate nuclei (Hoechst staining).
- FIG. 11 is a graph showing the results of comparison of the fluorescent intensity of lipid staining with Nile red of the three-dimensional tissue on day 7 of differentiation in Production Example 6.
- the present invention provides a method for producing a three-dimensional tissue containing mature adipocytes, comprising incubating cells containing at least adipose-derived stem cells in the presence of a TGF ⁇ type I receptor inhibitor.
- the term "three-dimensional tissue” means an aggregate of cells (massive cell aggregate) artificially produced by cell culture and arranged three-dimensionally.
- the three-dimensional tissue contains an extracellular matrix component, which will be described later, cells are three-dimensionally arranged via the extracellular matrix component.
- the shape of the three-dimensional tissue is not particularly limited, and examples thereof include sheet-like, spherical, substantially spherical, ellipsoidal, substantially ellipsoidal, hemispherical, substantially hemispherical, semicircular, substantially semicircular, A rectangular parallelepiped shape, a substantially rectangular parallelepiped shape, etc. are mentioned.
- the biological tissue includes sweat glands, lymphatic vessels, sebaceous glands, etc., and has a more complicated structure than a three-dimensional tissue. Therefore, the three-dimensional tissue and living tissue can be easily distinguished.
- Cells as used herein are not particularly limited, but may be, for example, cells derived from mammals such as monkeys, dogs, cats, rabbits, pigs, cows, mice, and rats.
- the site of cell origin is not particularly limited, and may be somatic cells derived from bones, muscles, internal organs, nerves, brains, bones, skin, blood, or the like, or germ cells.
- the cells may be stem cells, or cultured cells such as primary cultured cells, subcultured cells and cell line cells.
- stem cell means a cell with self-renewal ability and pluripotency.
- Stem cells include pluripotent stem cells that have the ability to differentiate into any cell tumor and tissue stem cells (also called somatic stem cells) that have the ability to differentiate into specific cell tumors.
- Pluripotent stem cells include, for example, embryonic stem cells (ES cells), somatic cell-derived ES cells (ntES cells) and induced pluripotent stem cells (iPS cells).
- Tissue stem cells include, for example, mesenchymal stem cells (eg, adipose-derived stem cells, bone marrow-derived stem cells), hematopoietic stem cells and neural stem cells.
- the cells include at least adipose-derived stem cells.
- the origin of adipose-derived stem cells is not particularly limited, and for example, stem cells collected from subcutaneous adipose tissue, epicardium-derived adipose tissue, or the like may be used.
- stem cells collected from subcutaneous adipose tissue, epicardium-derived adipose tissue, or the like may be used.
- the three-dimensional tissue body containing mature adipocytes produced by the method of the present embodiment is finally used as a tissue at a specific part of the living body, it is derived from a tissue corresponding to the tissue at that part. is preferred.
- the adipose-derived stem cells for example, bovine-derived, horse-derived, mouse-derived, rat-derived, and swine-derived stem cells may be used.
- differentiation into mature adipocytes can be promoted even when bovine adipose-derived stem cells, which are known to be particularly difficult to differentiate into mature adipocytes, are used. Therefore, it is preferable to use bovine-derived adipose-derived stem cells because the effects of the present invention are more pronounced.
- the cells may further contain cells other than adipose-derived stem cells.
- cells other than adipose-derived stem cells include mesenchymal cells such as fibroblasts, chondrocytes, and osteoblasts, colon cancer cells (e.g., human colon cancer cells (HT29)), liver cancer cells, and the like.
- cancer cells cardiomyocytes, epithelial cells (e.g., human gingival epithelial cells), lymphatic endothelial cells, nerve cells, dendritic cells, hepatocytes, adhesive cells (e.g., immune cells), smooth muscle cells (e.g., aortic smooth muscle cells (Aorta-SMC)), pancreatic islet cells, keratinocytes (eg, human epidermal keratinocytes), and the like.
- epithelial cells e.g., human gingival epithelial cells
- lymphatic endothelial cells nerve cells
- dendritic cells dendritic cells
- hepatocytes adhesive cells (e.g., immune cells)
- smooth muscle cells e.g., aortic smooth muscle cells (Aorta-SMC)
- pancreatic islet cells keratinocytes (eg, human epidermal keratinocytes), and the like.
- keratinocytes
- the three-dimensional tissue in this embodiment contains mature adipocytes.
- 90% or more of the total number of adipocytes are preferably mature adipocytes, and more preferably all are mature adipocytes.
- adipocyte means all adipocytes other than adipose-derived stem cells, and includes mature adipocytes and adipocytes that are not included in adipose-derived stem cells.
- lipid droplets can be used as an indicator of the maturity of fat cells.
- Lipid droplets are intracellular organelles that store lipids such as triglycerides (neutral fats) and cholesterol.
- lipids such as triglycerides (neutral fats) and cholesterol.
- adipose tissue-specific proteins such as perilipin
- the size of the lipid droplets of mature adipocytes varies, for example, when the average value of the lipid droplet size is 20 ⁇ m or more, the adipocytes are mature to some extent, i.e., mature adipocytes can be assumed to be
- the fat cell content is, for example, 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, or 30% or more with respect to the total number of cells in the three-dimensional tissue, It may be 95% or less, 90% or less, 80% or less, or 75% or less.
- the content of mature adipocytes is, for example, 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, or 30% or more with respect to the total number of cells in the three-dimensional tissue. may be 95% or less, 90% or less, 80% or less, or 75% or less.
- the three-dimensional tissue may further contain cells other than mature adipocytes.
- cells other than mature adipocytes include mesenchymal cells such as fibroblasts, chondrocytes, and osteoblasts, colon cancer cells (e.g., human colon cancer cells (HT29)), liver cancer cells, and the like.
- cancer cells cardiomyocytes, epithelial cells (e.g., human gingival epithelial cells), lymphatic endothelial cells, nerve cells, dendritic cells, hepatocytes, adhesive cells (e.g., immune cells), smooth muscle cells (e.g., aortic smooth muscle cells (Aorta-SMC)), pancreatic islet cells, keratinocytes (eg, human epidermal keratinocytes), and the like.
- the present invention has the effect of promoting the differentiation of adipose-derived stem cells into mature adipocytes, the effect of the present invention becomes more pronounced. It is preferably 10% or less, more preferably 5% or less of the total number of cells in the tissue, and further preferably does not contain adipose-derived stem cells.
- the three-dimensional tissue may have a vascular network between cells.
- a vascular network is formed between cells, it is expected that the three-dimensional tissue can be maintained for a long period of time, and that the three-dimensional tissue will be easier to engraft when transplanted into a mammal or the like.
- Having a vascular network between cells means having a structure in which branched blood vessels extend between cells so as to surround cells, similar to living tissue. Whether or not a vascular network similar to that of the living tissue is formed is determined based on, for example, the number of branched blood vessels and/or the diversity of the length between branched blood vessels and/or the diameter of the blood vessels in the living tissue. can be done. For example, the average number of branched blood vessels in the three-dimensional tissue relative to the average number of branched blood vessels in the living tissue is 80% to 150%, 85% to 130%, or 90% to 120%. In some cases, it may be determined that the number of branches is similar to that of blood vessels in living tissue.
- the average value of the branching number of blood vessels in the three-dimensional tissue is 2.5 or more and 4.5 or less, or 3.0 or more and 4.2 or less, it is similar to the number of blood vessels branching in the biological tissue. It may be determined that For example, the average value of the length between branches of blood vessels in the three-dimensional tissue relative to the average value of the length between branches of blood vessels in living tissue is 80% or more and 150% or less, 85% or more and 130% or less, and 90%. % or more and 120% or less, it may be determined that the length is similar to the length between branches of blood vessels in living tissue. Both large and small blood vessels are observed in living tissue.
- a three-dimensional tissue containing mature adipocytes preferably has a vascular network between adipocytes.
- a vascular network it is preferable not only to have a vascular network, but also to have adipocytes surrounded by blood vessels close to the living tissue.
- the average lipid droplet size of adipocytes in the three-dimensional tissue according to the present embodiment is 20 ⁇ m to 180 ⁇ m, or 100 ⁇ m to 180 ⁇ m
- the three-dimensional tissue is similar to fat cells in living tissue You may judge that you have fat cells of
- the biological tissue and the three-dimensional tissue are compared under the same conditions (for example, per fixed volume, per fixed area in the case of image analysis, per fixed sample, etc.).
- the thickness of the three-dimensional tissue is preferably 10 ⁇ m or more, more preferably 100 ⁇ m or more, and even more preferably 1000 ⁇ m or more.
- Such a three-dimensional tissue has a structure closer to that of a living tissue, and is suitable as a substitute for experimental animals and as a transplant material.
- the upper limit of the thickness of the three-dimensional tissue is not particularly limited, but may be, for example, 10 mm or less, 3 mm or less, 2 mm or less, or 1.5 mm or less. It may be there, or it may be 1 mm or less.
- the "thickness of the three-dimensional tissue” means the distance between both ends in the direction perpendicular to the main surface when the three-dimensional tissue is in the form of a sheet or a rectangular parallelepiped.
- the thickness means the distance at the thinnest part of the main surface.
- the three-dimensional tissue when the three-dimensional tissue is spherical or approximately spherical, it means its diameter. Furthermore, when the three-dimensional tissue is ellipsoidal or substantially ellipsoidal, it means the minor axis thereof. When the three-dimensional tissue has a substantially spherical or substantially ellipsoidal shape and has irregularities on the surface, the thickness is the distance between two points where a straight line passing through the center of gravity of the three-dimensional tissue and the surface intersect. means the shortest distance.
- the method of this embodiment includes incubating cells containing at least adipose-derived stem cells in the presence of a TGF ⁇ type I receptor inhibitor. Incubation in the presence of a TGF ⁇ type I receptor inhibitor promotes the differentiation of adipose-derived stem cells into mature adipocytes. In the method of the present embodiment, differentiation is promoted while the adipose-derived stem cells are contained in the three-dimensional tissue, or in a situation where the three-dimensional tissue is formed so that the adipose-derived stem cells are contained in the tissue. By promoting differentiation, it is possible to finally produce a three-dimensional tissue containing vascular cells.
- incubating cells containing at least adipose-derived stem cells in the presence of a TGF ⁇ type I receptor inhibitor may be performed by incubating only the cells in the presence of the TGF ⁇ type I receptor inhibitor, the cells and the extracellular matrix
- the components may be mixed and incubated in the presence of the TGF ⁇ type I receptor inhibitor, and in the presence of the TGF ⁇ type I receptor inhibitor in a state in which a three-dimensional tissue containing cells and extracellular matrix components is formed may be incubated at
- TGF ⁇ type I receptor inhibitors include inhibitors of ALK5, ALK2, ALK4 and ALK7, which are TGF ⁇ R1 kinases.
- the TGF ⁇ type I receptor inhibitor is not particularly limited as long as it has an inhibitory effect on the TGF ⁇ type I receptor.
- ALK5, ALK4 and ALK7 inhibitors include, for example, 4-[4-(1,3-benzodioxyol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide
- ALK5 inhibitors include, for example, 2-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1,5-naphthyridine, 2-(3-(6-methyl Pyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, hydrochloride, N-(2-fluorophenyl)-4-([1,2,4]triazolo[1,5- a]pyridin-6-yl)-5-(6-methyl-2-pyridyl)-1H-imidazole-2-methanamine and the like.
- Incubating in the presence of a TGF ⁇ type I receptor inhibitor may mean, for example, incubating (cultivating) cells containing at least adipose-derived stem cells in a medium containing a TGF ⁇ type I receptor inhibitor.
- cells containing at least adipose-derived stem cells are treated with one or more fatty acids selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.
- Incubation may be performed in the presence of the above fatty acids, or may be performed in the presence of elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid. Incubation may also be performed in the presence of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid. Incubation in the presence of these fatty acids further promotes the differentiation of adipose-derived stem cells into mature adipocytes.
- the incubation in the presence of the fatty acid may or may not be performed simultaneously with the incubation in the presence of the TGF ⁇ type I receptor inhibitor.
- the fatty acids described above may be included in the medium along with the TGF ⁇ type I receptor inhibitor.
- a medium containing the fatty acid and the TGF ⁇ type I receptor inhibitor in advance may be used, or the TGF ⁇ type I receptor inhibitor may be added to the medium containing the fatty acid, and the TGF ⁇ type I receptor inhibitor may be added.
- the fatty acid may be added to the medium containing the body inhibitor.
- the cells may be incubated in a medium containing the TGF ⁇ type I receptor inhibitor, and the TGF ⁇ type I receptor inhibitor After incubating the cells in a medium containing, the cells may be incubated in a medium containing the fatty acid.
- the medium may be a solid medium or a liquid medium, preferably a liquid medium.
- the medium include Eagle's MEM medium, DMEM, Modified Eagle medium (MEM), Minimum Essential medium, RPMI, and GlutaMax medium.
- the liquid medium may be in the form of a gel such as fibrin gel, hydrogel, matrigel, collagen gel and gelatin gel. Cells may be added to a gelled liquid medium, or a liquid medium containing cells may be gelled before use.
- the medium may be a serum-supplemented medium or a serum-free medium.
- the medium may be a mixed medium in which two types of medium are mixed.
- the amount of the TGF ⁇ type I receptor inhibitor may be an amount sufficient for each adipose - derived stem cell to come into contact with the inhibitor. ⁇ 11 mol to 2.0 ⁇ 10 ⁇ 8 mol, or 1.0 ⁇ 10 ⁇ 9 mol to 2.0 ⁇ 10 ⁇ 8 mol, for example, for 5 ⁇ 10 6 cells of adipose-derived stem cells, It may be from 1.0 ⁇ 10 ⁇ 10 mol to 1.0 ⁇ 10 ⁇ 7 mol, or from 5.0 ⁇ 10 ⁇ 9 mol to 1.0 ⁇ 10 ⁇ 7 mol.
- the TGF ⁇ type I receptor inhibitor may be, for example, 6.0 ng to 6.0 ⁇ g, or 300 ng to 6.0 ⁇ g, for 1 ⁇ 10 6 cells of adipose-derived stem cells. It may be 30 ng to 30 ⁇ g, or 1500 ng to 30 ⁇ g for ⁇ 10 6 cells.
- the content of the TGF ⁇ type I receptor inhibitor in the medium is, for example, 0.1 ⁇ M or more and 100 ⁇ M or less. 5 ⁇ M or more and 50 ⁇ M or less, 1 ⁇ M or more and 10 ⁇ M or less, or 2 ⁇ M or more and 8 ⁇ M or less, or 0.5 ⁇ M or more, 0.7 or more, 1 ⁇ M or more, 2 ⁇ M or more, 3 ⁇ M or more, 4 ⁇ M or more, or 5 ⁇ M or more. , 20 ⁇ M or less, 15 ⁇ M or less, 12 ⁇ M or less, 10 ⁇ M or less, 8 ⁇ M or less, or 7 ⁇ M or less.
- the content of each fatty acid in the medium is, for example, 0.1 ⁇ M or more and 200 ⁇ M or less, 2 ⁇ M or more and 100 ⁇ M or less, 10 ⁇ M or more and 60 ⁇ M or less, or 30 ⁇ M or more.
- Each fatty acid is, for example, 2.0 ⁇ 10 ⁇ 11 mol to 4.0 ⁇ 10 ⁇ 8 mol, or 1.0 ⁇ 10 ⁇ 9 mol to 2.0 ⁇ per 1 ⁇ 10 6 cells of adipose-derived stem cells. It may be 10 ⁇ 8 mol.
- the weight of each fatty acid may be, for example, 6 ng to 15 ⁇ g, or 250 ng to 10 ⁇ g for 1 ⁇ 10 6 cells of adipose-derived stem cells.
- the cell density in the medium before incubation can be appropriately determined according to the shape and thickness of the target three-dimensional tissue, the size of the incubator, and the like.
- the cell density in the medium can be 1-10 8 cells/mL, 10 3 -10 7 cells/mL.
- Incubation is not particularly limited, and can be carried out under suitable conditions according to the type of cells to be cultured.
- the incubation temperature may be 20°C to 40°C, or 30°C to 37°C.
- the pH of the medium may be 6-8, or 7.2-7.4.
- the incubation time may be 24 hours or more and 336 hours or less, may be 72 hours or more and 336 hours or less, may be 96 hours or more and 384 hours or less, or may be 96 hours or more and 288 hours or less. good too.
- the incubation time after addition of the TGF ⁇ type I receptor inhibitor and/or the fatty acid may be 24 hours or more and 336 hours or less, may be 72 hours or more and 336 hours or less, or may be 96 hours or more. It may be 384 hours or less, or it may be 96 hours or more and 288 hours or less.
- the incubator (support) used for cell culture is not particularly limited, and may be, for example, a well insert, a low-adhesion plate, or a plate having a U-shaped or V-shaped bottom surface.
- the cells may be cultured while adhered to the support, the cells may be cultured without being adhered to the support, or the cells may be separated from the support during culture and cultured.
- a U-shaped or V-shaped bottom surface that inhibits adhesion of the cells to the support is used. It is preferable to use a plate with a low adsorption or a low adsorption plate.
- the method of this embodiment may comprise incubating cells containing at least adipose-derived stem cells with fragmented extracellular matrix components in the presence of a TGF ⁇ type I receptor inhibitor.
- a TGF ⁇ type I receptor inhibitor By incubating with the fragmented extracellular matrix component, it is possible to obtain a three-dimensional tissue in which cells are three-dimensionally arranged via the fragmented extracellular matrix component. It is preferable that the fragmented extracellular matrix component is a three-dimensional tissue that is arranged in the interstices between the cells. Cells among cells may be allogeneic cells or heterologous cells.
- the fragmented extracellular matrix component may be added to the medium at the same time as the TGF ⁇ type I receptor inhibitor, and may be added to the medium prior to the TGF ⁇ type I receptor inhibitor. It may be added to the medium or may be added to the medium after the TGF ⁇ type I receptor inhibitor.
- Extracellular matrix component refers to an aggregate of extracellular matrix molecules formed by a plurality of extracellular matrix molecules.
- Extracellular matrix means a substance that exists outside cells in an organism. Any substance can be used as the extracellular matrix as long as it does not adversely affect the growth of cells and the formation of cell aggregates. Specific examples include, but are not limited to, collagen, elastin, proteoglycan, fibronectin, hyaluronic acid, laminin, vitronectin, tenascin, entactin and fibrillin. These extracellular matrix components may be used singly or in combination.
- the extracellular matrix component may, for example, contain or be a collagen component.
- the extracellular matrix component in the present embodiment is preferably a substance existing outside animal cells, that is, an animal extracellular matrix component.
- the extracellular matrix molecule may be a modification or variant of the above extracellular matrix molecule, or a polypeptide such as a chemically synthesized peptide, as long as it does not adversely affect cell growth and formation of cell aggregates. good.
- the extracellular matrix molecule may have repeats of the Gly-XY sequence characteristic of collagen.
- Gly represents a glycine residue
- X and Y each independently represent any amino acid residue.
- a plurality of Gly-XY may be the same or different.
- the proportion of the sequence represented by Gly-XY in the total amino acid sequence may be 80% or more, preferably 95%. That's it.
- the extracellular matrix molecule may be a polypeptide having an RGD sequence.
- the RGD sequence refers to a sequence represented by Arg-Gly-Asp (arginine residue-glycine residue-aspartic acid residue). Having an RGD sequence further promotes cell adhesion, making it more suitable as a scaffold material for cell culture, for example.
- Extracellular matrix molecules containing a sequence represented by Gly-XY and an RGD sequence include collagen, fibronectin, vitronectin, laminin, cadherin and the like.
- Collagen includes, for example, fibrous collagen and non-fibrous collagen.
- Fibrous collagen means collagen that is the main component of collagen fibers, and specifically includes type I collagen, type II collagen, type III collagen, and the like.
- Non-fibrillar collagens include, for example, type IV collagen.
- Proteoglycans include, but are not limited to, chondroitin sulfate proteoglycans, heparan sulfate proteoglycans, keratan sulfate proteoglycans, and dermatan sulfate proteoglycans.
- the extracellular matrix component may contain at least one selected from the group consisting of collagen, laminin and fibronectin, and preferably contains collagen, since the effects of the present invention are more pronounced.
- the collagen is preferably fibrillar collagen, more preferably type I collagen.
- Commercially available collagen may be used as the fibrillar collagen, and a specific example thereof is porcine skin-derived type I collagen manufactured by Nippon Ham Co., Ltd.
- the extracellular matrix component may be an animal-derived extracellular matrix component.
- animal species from which extracellular matrix components are derived include, but are not limited to, humans, pigs, and bovines.
- As the extracellular matrix component a component derived from one kind of animal may be used, or a combination of components derived from a plurality of kinds of animals may be used.
- Fragmentation means reducing the size of aggregates of extracellular matrix molecules to a smaller size. Fragmentation may be performed under conditions that cleave bonds within extracellular matrix molecules, or under conditions that do not cleave bonds within extracellular matrix molecules. Extracellular matrices that have been fragmented by the application of physical force usually do not change their molecular structure (the molecular structure is maintained) unlike enzymatic treatment. Fragmented extracellular matrix components may contain defibrated extracellular matrix components (fibrillated extracellular matrix components), which are components obtained by defibrating the above-described extracellular matrix components by applying physical force. . Defibrillation is one mode of fragmentation, and is performed under conditions that do not break bonds within extracellular matrix molecules, for example.
- the method for fragmenting extracellular matrix components is not particularly limited.
- the extracellular matrix components may be defibrated by applying physical force using an ultrasonic homogenizer, a stirring homogenizer, a high-pressure homogenizer, or the like.
- the extracellular matrix component may be homogenized as it is, or may be homogenized with an aqueous medium such as physiological saline or an organic solvent such as ethanol. It is also possible to obtain millimetre-size and nanometer-size fibrillated extracellular matrix components by adjusting the homogenization time, number of times, and the like.
- the defibrated extracellular matrix component can also be obtained by defibrating by repeating freezing and thawing.
- the fragmented extracellular matrix component may at least partially contain a defibrated extracellular matrix component. Moreover, the fragmented extracellular matrix component may consist of only the defibrated extracellular matrix component. That is, the fragmented extracellular matrix component may be a defibrated extracellular matrix component.
- the defibrated extracellular matrix component preferably contains a fibrillated collagen component (fibrillated collagen component).
- the defibrated collagen component preferably maintains the triple helical structure derived from collagen.
- the defibrillated collagen component may be a component that partially maintains the triple helical structure derived from collagen.
- the shape of the fragmented extracellular matrix component includes, for example, a fibrous shape.
- the fibrous shape means a shape composed of filamentous collagen components or a shape composed of filamentous extracellular matrix components crosslinked between molecules. At least some of the fragmented extracellular matrix components may be fibrous.
- Fibrous extracellular matrix components include thin filaments (fibrils) formed by aggregation of multiple filamentous extracellular matrix molecules, filaments formed by further aggregation of filaments, and these filaments. Including defibrated ones. The RGD sequence is preserved without disruption in the fibrous extracellular matrix component.
- the average length of the fragmented extracellular matrix component may be 100 nm or more and 400 ⁇ m or less, and may be 100 nm or more and 200 ⁇ m or less. In one embodiment, the average length of the fragmented extracellular matrix component may be 5 ⁇ m or more and 400 ⁇ m or less, 10 ⁇ m or more and 400 ⁇ m or less, 22 ⁇ m or more and 400 ⁇ m or less, or 100 ⁇ m or more and 400 ⁇ m or less. good. In another embodiment, the average length of the fragmented extracellular matrix component may be 100 ⁇ m or less, 50 ⁇ m or less, or 30 ⁇ m or less from the viewpoint of further excellent redispersibility.
- the fragmented extracellular matrix component is preferably a fragmented collagen component having an average length within the above range, and more preferably a fibrillated collagen component having an average length within the above range.
- the average diameter of the fragmented extracellular matrix component may be 10 nm or more and 30 ⁇ m or less, 30 nm or more and 30 ⁇ m or less, 50 nm or more and 30 ⁇ m or less, 100 nm or more and 30 ⁇ m or less, or 1 ⁇ m or more and 30 ⁇ m or less. 2 ⁇ m or more and 30 ⁇ m or less, 3 ⁇ m or more and 30 ⁇ m or less, 4 ⁇ m or more and 30 ⁇ m or less, or 5 ⁇ m or more and 30 ⁇ m or less.
- the fragmented extracellular matrix component is preferably a fragmented collagen component having an average diameter within the above range, and more preferably a fibrillated collagen component having an average diameter within the above range.
- the average length and average diameter of the fragmented extracellular matrix components can be determined by measuring individual fragmented extracellular matrix components with an optical microscope and analyzing the images.
- average length means the average length of the measured sample in the longitudinal direction
- average diameter means the average length of the measured sample in the direction orthogonal to the longitudinal direction. means.
- the fragmented extracellular matrix component may contain, for example, a fragmented collagen component or consist of a fragmented collagen component.
- the “fragmented collagen component” means a fragmented collagen component such as a fibrillar collagen component that maintains a triple helical structure.
- the average length of the fragmented collagen component is preferably 100 nm to 200 ⁇ m, more preferably 22 ⁇ m to 200 ⁇ m, even more preferably 100 ⁇ m to 200 ⁇ m.
- the average diameter of the fragmented collagen component is preferably 50 nm to 30 ⁇ m, more preferably 4 ⁇ m to 30 ⁇ m, even more preferably 20 ⁇ m to 30 ⁇ m.
- At least part of the fragmented extracellular matrix components may be crosslinked intermolecularly or intramolecularly.
- the extracellular matrix component may be intramolecularly or intermolecularly crosslinked with the extracellular matrix molecules that make up the extracellular matrix component.
- cross-linking methods include physical cross-linking by applying heat, ultraviolet rays, radiation, etc., and chemical cross-linking by cross-linking agents, enzymatic reactions, etc., but the method is not particularly limited. Physical cross-linking is preferred from the standpoint of not interfering with cell growth. Cross-linking (physical cross-linking and chemical cross-linking) may be cross-linking via covalent bonds.
- the crosslinks may be formed between collagen molecules (triple helix structure) or between collagen fibrils formed by the collagen molecules.
- the cross-linking may be thermal cross-linking (thermal cross-linking). Thermal crosslinking can be performed, for example, by heat treatment under reduced pressure using a vacuum pump.
- the extracellular matrix component is crosslinked by forming a peptide bond (-NH-CO-) between the amino group of the collagen molecule and the carboxyl group of the same or another collagen molecule. you can
- the extracellular matrix component can also be crosslinked by using a crosslinker.
- the cross-linking agent may be, for example, one capable of cross-linking carboxyl groups and amino groups, or one capable of cross-linking amino groups.
- As the crosslinking agent for example, aldehyde-based, carbodiimide-based, epoxide-based and imidazole-based crosslinking agents are preferable from the viewpoint of economy, safety and operability.
- glutaraldehyde 1-ethyl-3-(3 -dimethylaminopropyl)carbodiimide hydrochloride, 1-cyclohexyl-3-(2-morpholinyl-4-ethyl)carbodiimide sulfonate, and other water-soluble carbodiimides.
- the quantification of the degree of cross-linking can be appropriately selected according to the type of extracellular matrix component, cross-linking means, and the like.
- the degree of cross-linking may be 1% or more, 2% or more, 4% or more, 8% or more, or 12% or more, and may be 30% or less, 20% or less, or 15% or less.
- the degree of cross-linking is within the above range, the extracellular matrix molecules can be appropriately dispersed, and the redispersibility after dry storage is good.
- the degree of cross-linking can be quantified based on the TNBS (trinitrobenzenesulfonic acid) method.
- the degree of cross-linking by the TNBS method may be within the range described above.
- the degree of cross-linking by the TNBS method is the proportion of amino groups used for cross-linking among the amino groups in the extracellular matrix.
- the extracellular matrix component contains a collagen component
- the degree of cross-linking measured by the TNBS method is preferably within the above range.
- the degree of cross-linking may be calculated by quantifying the carboxyl groups.
- water-insoluble extracellular matrix components may be quantified by the TBO (toluidine blue O) method.
- the degree of cross-linking by the TBO method may be within the range described above.
- the content of extracellular matrix components in the three-dimensional tissue may be 0.01 to 90% by mass, preferably 10 to 90% by mass, preferably 10 to 90% by mass, based on the three-dimensional tissue (dry weight). It is preferably 80% by mass, preferably 10 to 70% by mass, preferably 10 to 60% by mass, preferably 1 to 50% by mass, preferably 10 to 50% by mass. is preferred, 10 to 30 mass % is more preferred, and 20 to 30 mass % is more preferred.
- extracellular matrix component in the three-dimensional tissue means an extracellular matrix component that constitutes the three-dimensional tissue, and may be derived from endogenous extracellular matrix components or exogenous extracellular matrix components. It may be derived from matrix components.
- Endogenous extracellular matrix components means extracellular matrix components produced by extracellular matrix-producing cells.
- extracellular matrix-producing cells include mesenchymal cells such as fibroblasts, chondrocytes, and osteoblasts described above. Endogenous extracellular matrix components may be fibrous or non-fibrous.
- Exogenous extracellular matrix component means an extracellular matrix component supplied from the outside. Exogenous extracellular matrix components may be derived from the same or different animal species as endogenous extracellular matrix components. Examples of animal species from which it is derived include humans, pigs, and bovines. Exogenous extracellular matrix components may also be artificial extracellular matrix components.
- the extrinsic extracellular matrix component is also referred to as an "exogenous collagen component", and the term “exogenous collagen component”, which means a collagen component supplied from the outside, includes a plurality of collagen components. It is an aggregate of collagen molecules formed by the collagen molecules of , and specifically includes fibrillar collagen, non-fibrillar collagen, and the like.
- the exogenous collagen component is fibrillar collagen.
- the fibrillar collagen means a collagen component that is the main component of collagen fibers, and examples thereof include type I collagen, type II collagen, and type III collagen.
- Commercially available collagen may be used as the fibrillar collagen, and specific examples thereof include porcine skin-derived type I collagen manufactured by Nippon Ham Co., Ltd.
- Exogenous non-fibrillar collagens include, for example, type IV collagen.
- the animal species from which the exogenous extracellular matrix component is derived may be different from the cell. Moreover, when the cells contain extracellular matrix-producing cells, the animal species from which the exogenous extracellular matrix component is derived may be different from the extracellular matrix-producing cells. Thus, an exogenous extracellular matrix component may be a heterologous extracellular matrix component.
- the content of extracellular matrix components constituting the three-dimensional tissue is the endogenous extracellular matrix component and the fragmented cell means the total amount of outer matrix components.
- the extracellular matrix content can be calculated from the volume of the obtained three-dimensional tissue and the mass of the decellularized three-dimensional tissue.
- the method for quantifying the amount of collagen component in the three-dimensional tissue includes, for example, the following method for quantifying hydroxyproline.
- a sample is prepared by mixing hydrochloric acid (HCl) with a solution in which a three-dimensional tissue is dissolved, incubating at a high temperature for a predetermined time, returning to room temperature, and diluting the centrifuged supernatant to a predetermined concentration. After treating the hydroxyproline standard solution in the same manner as the sample, prepare the standard by serially diluting it. Each sample and standard is treated with a hydroxyproline assay buffer and a detection reagent, and the absorbance at 570 nm is measured.
- the amount of collagen component is calculated by comparing the absorbance of the sample with the standard.
- the three-dimensional tissue may be directly suspended in high-concentration hydrochloric acid, and the dissolved solution may be centrifuged to recover the supernatant, which may be used to quantify the collagen component.
- the three-dimensional tissue to be dissolved may be in a state as it is recovered from the culture medium, or may be dissolved in a state in which a liquid component is removed by performing a drying treatment after recovery.
- the weight after drying should be used as the standard. is preferred.
- examples of the method for quantifying the amount of collagen components include the following methods.
- sample preparation The whole amount of the freeze-dried three-dimensional tissue is mixed with 6 mol/L HCl, incubated in a heat block at 95° C. for 20 hours or more, and then returned to room temperature. After centrifugation at 13000 g for 10 minutes, the supernatant of the sample solution is recovered. After appropriately diluting with 6 mol/L HCl so that the results in the measurement described below fall within the range of the calibration curve, a sample is prepared by diluting 200 ⁇ L with 100 ⁇ L of ultrapure water. 35 ⁇ L of sample is used.
- the collagen component occupying the three-dimensional tissue may be defined by its area ratio or volume ratio.
- "Define by area ratio or volume ratio” means, for example, collagen components in the three-dimensional tissue by known staining techniques (e.g., immunostaining using anti-collagen antibody, or Masson's trichrome staining) Other tissues It means calculating the ratio of the existing area of the collagen component to the entire three-dimensional tissue body by using macroscopic observation, various microscopes, image analysis software, etc. after making it distinguishable from the structure.
- the area ratio it is not limited by any cross section or surface in the three-dimensional tissue, but for example, when the three-dimensional tissue is a spherical body etc., it passes through the approximate center It may be defined by a cross-sectional view.
- the ratio of the area is 0.01 to 99% based on the total area of the three-dimensional tissue, and 1 to 99%. preferably 5 to 90%, preferably 7 to 90%, preferably 20 to 90%, more preferably 50 to 90%.
- the “collagen component in the three-dimensional tissue” is as described above.
- the ratio of the area of the collagen component that constitutes the three-dimensional tissue refers to the ratio of the total area of the endogenous collagen component and the exogenous collagen component.
- the ratio of the area of the collagen component is obtained, for example, by staining the obtained three-dimensional tissue with Masson's trichrome, and comparing the area of the blue-stained collagen component to the total area of the cross section passing through the approximate center of the three-dimensional tissue. It can be calculated as a percentage.
- the three-dimensional tissue has a trypsin concentration of 0.25%, a temperature of 37° C., a pH of 7.4, and a reaction time of 15 minutes. It is more preferably 90% or more, and even more preferably 90% or more. Such a three-dimensional tissue is stable and resistant to enzymatic degradation during or after culturing.
- the survival rate can be calculated, for example, from the mass of the three-dimensional tissue before and after trypsinization.
- the three-dimensional tissue may have a residual rate of 70% or more after collagenase treatment at a collagenase concentration of 0.25%, a temperature of 37 ° C., pH 7.4, and a reaction time of 15 minutes, or 80% or more. is more preferable, and 90% or more is even more preferable.
- Such a three-dimensional tissue is stable and resistant to enzymatic degradation during or after culturing.
- Incubating a cell containing at least an adipose-derived stem cell with a fragmented extracellular matrix component in the presence of a TGF ⁇ type I receptor inhibitor means, for example, that cells are incubated with a TGF ⁇ type I receptor inhibitor and a fragmented extracellular matrix component. It may be incubating (cultivating) in a medium containing. At that time, for example, a medium containing a fragmented extracellular matrix component and a TGF ⁇ type I receptor inhibitor may be used in advance, and the TGF ⁇ type I receptor inhibitor is added to the medium containing the fragmented extracellular matrix component. Alternatively, fragmented extracellular matrix components may be added to the medium containing the TGF ⁇ type I receptor inhibitor.
- the TGF ⁇ type I receptor inhibitor and/or the fatty acid mentioned above may be contained in the aqueous medium, added before incubation, or added during incubation.
- the aqueous medium may be the same as during incubation or may be different.
- the cells may be contacted with the fragmented extracellular matrix component in an aqueous medium and incubated, followed by further incubation in the presence of the TGF ⁇ type I receptor inhibitor and/or the fatty acid.
- the time for contacting and incubating the cells and the fragmented extracellular matrix component in an aqueous medium may be, for example, 12 hours to 72 hours.
- Aqueous medium means a liquid containing water as an essential component.
- the aqueous medium is not particularly limited as long as it allows the fragmented extracellular matrix components to exist stably.
- aqueous media include physiological saline such as phosphate buffered saline (PBS), Dulbecco's Modified Eagle medium (DMEM), and liquid media such as vascular endothelial cell-specific medium (EGM2), but are limited thereto. not.
- the pH of the aqueous medium is preferably within a range that does not adversely affect cell growth and formation of cell aggregates.
- the pH of the aqueous medium may be, for example, 7.0 or more and 8.0 or less from the viewpoint of reducing the load on the cells when injected into the cells.
- the pH of the aqueous medium is 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9. , or 8.0.
- the aqueous medium preferably has a buffering capacity in the above pH range, and is more preferably a liquid medium.
- the liquid medium is not particularly limited, and a suitable medium can be selected according to the type of cells to be cultured.
- the medium examples include Eagle's MEM medium, DMEM, Modified Eagle medium (MEM), Minimum Essential medium, RPMI, and GlutaMax medium.
- the medium may be a serum-supplemented medium or a serum-free medium.
- the liquid medium may be a mixed medium in which two or more types of medium are mixed.
- the contacting step includes a method of mixing an aqueous medium containing fragmented extracellular matrix components and an aqueous medium containing cells, a method of adding cells to an aqueous medium containing fragmented extracellular matrix components, and a method of adding cells to an aqueous medium containing fragmented extracellular matrix components.
- a method of adding an aqueous medium containing an extracellular matrix component to a culture medium a method of adding cells to an aqueous medium containing an extracellular matrix component, and adding an extracellular matrix component and cells to a previously prepared aqueous medium.
- the methods include, but are not limited to.
- the concentration of the fragmented extracellular matrix component in the contact step can be appropriately determined according to the shape and thickness of the target three-dimensional tissue, the size of the incubator, and the like.
- the concentration of the fragmented extracellular matrix component in the aqueous medium in the contacting step may be 0.1-90% by mass, or 1-30% by mass.
- the amount of the fragmented extracellular matrix component in the contact step is, for example, 0.1 to 100 mg, 0.5 to 50 mg, 0.8 to 25 mg, 1.0 to 1.0 mg for 1.0 ⁇ 10 6 cells. 10 mg, 1.0-5.0 mg, 1.0-2.0 mg, or 1.0-1.8 mg, 0.7 mg or more, 1.1 mg or more, 1.2 mg or more, 1.3 mg or more Or it may be 1.4 mg or more, and may be 7.0 mg or less, 3.0 mg or less, 2.3 mg or less, 1.8 mg or less, 1.7 mg or less, 1.6 mg or less, or 1.5 mg or less.
- the mass ratio between the fragmented extracellular matrix components and the cells is preferably 1/1 to 1000/1, more preferably 9/1 to 900/1. is more preferable, and 10/1 to 500/1 is even more preferable.
- the amount of the fragmented extracellular matrix component in the contacting step is 0.1% to 10% by weight, 0.5% to 8% by weight, or 1% to 5% by weight relative to the weight of the entire medium. There may be.
- An embodiment of the method for producing a three-dimensional tissue may include mixing fibrinogen and thrombin simultaneously or separately in the contacting step, or after the contacting step and before incubation. By mixing fibrinogen and thrombin, they react to form fibrin.
- the content of fibrinogen may be, for example, 1-10 mg/mL, 2-8 mg/mL, or 5-6 mg/mL relative to the medium.
- the contacting step and before the incubation it may further comprise a step of co-sedimenting the fragmented extracellular matrix component and the cells in the aqueous medium.
- a step of co-sedimenting the fragmented extracellular matrix component and the cells in the aqueous medium By carrying out such steps, the distribution of fragmented extracellular matrix components and cells in the three-dimensional tissue becomes more uniform.
- Specific methods are not particularly limited, but include, for example, a method of centrifuging a culture solution containing fragmented extracellular matrix components and cells.
- the cell density in the medium before incubation described above may be the same as the cell density in the aqueous medium in the contacting step.
- the present invention also provides a method for promoting differentiation of adipose-derived stem cells, which comprises incubating cells containing at least adipose-derived stem cells in the presence of a TGF ⁇ type I receptor inhibitor.
- incubating adipose-derived stem cells in the presence of a TGF ⁇ type I receptor inhibitor can promote differentiation of adipose-derived stem cells into mature adipocytes.
- the method of the present embodiment can also be used in the production of tissues involving incubation of cells, and the production of tissues may be three-dimensional culture or two-dimensional culture.
- the method of the present embodiment promotes differentiation in a state where adipose-derived stem cells are contained in tissue bodies, or promotes differentiation in a situation where tissue bodies are formed such that adipose-derived stem cells are contained in tissue bodies. , thereby finally producing a tissue body containing mature adipocytes.
- adipose-derived stem cells it is only necessary to promote differentiation by contacting at least a portion of adipose-derived stem cells with a TGF ⁇ type I receptor inhibitor.
- TGF ⁇ type I receptor inhibitor it can also be applied to two-dimensional culture.
- the method of the present embodiment may be a method for promoting differentiation of adipose-derived stem cells in the above-described method for producing a three-dimensional tissue.
- the method of this embodiment may also include a step of contacting the cells with the fragmented extracellular matrix component in an aqueous medium before incubation.
- cells containing at least adipose-derived stem cells are selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid. Also provided is a method of promoting differentiation of adipose-derived stem cells comprising incubating in the presence of fatty acids of Further, in one embodiment, adipose-derived stem cells are incubated in the presence of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.
- Differentiation of adipose-derived stem cells into mature adipocytes can be promoted by incubating adipose-derived stem cells in the presence of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid. can.
- cells containing at least adipose-derived stem cells are fragmented together with extracellular matrix components selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.
- extracellular matrix components selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.
- a three-dimensional tissue in which cells are three-dimensionally arranged via the fragmented extracellular matrix component. It is preferably a three-dimensional tissue in which the fragmented extracellular matrix component is arranged in the interstices between the cells.
- the method of this embodiment may also include a step of contacting the cells with the fragmented extracellular matrix component in an aqueous medium before incubation.
- a collagen component (crosslinked collagen component) at least partially crosslinked was obtained. Before and after heating at 200° C., no significant change in the appearance of the collagen was observed. 50 mg of the crosslinked collagen component was placed in a 15 mL tube, 5 mL of ultrapure was added, and the mixture was homogenized for 6 minutes using a homogenizer (As One VH-10) to defibrate the crosslinked collagen component.
- a homogenizer As One VH-10
- CMF defibrillated collagen component
- the cells, reagents, preparation method, and the like used in the preparation of the three-dimensional tissue are as follows.
- (cells and collagen) ⁇ FBS (Thermo Fisher, Gibco) ⁇ Subcutaneous adipose-derived stem cells (ADSC, derived from bovine, collected from beef for meat by a conventional method) ⁇ Erucic acid (Sigma #E3385) ⁇ Elaidic acid (Sigma #E4637) ⁇ Oleic acid (Sigma #O1008) ⁇ Palmitoleic acid (Sigma #P9417) ⁇ Myristoleic acid (Sigma #M3525) Phytanic acid (Sigma #P4060 or LaRoda Fine Chemicals 11-1600) ⁇ Pristanoic acid (Sigma #P6617 or LaRoda Fine Chemicals 11-1500) ⁇ Bovine plasma-derived fibrinogen type IS (Sigma #F8630)
- DMEM medium high glucose, Nacalai Tesque
- fibrinogen stock solution Weigh 50 mg of fibrinogen into an Eppendorf tube and immediately add 1 mL of DMEM (0% FBS, 1% antibiotics). After mixing by manually shaking the tube, place in a water bath at 37°C for 3 to 5 minutes, filter through a filter with a pore size of 0.2 ⁇ m, and aliquot into an Eppendorf tube for use.
- Production example 2 FBS non-fibrillated collagen component containing 1.2% by weight (final concentration), 6 mg/mL (final concentration) fibrinogen, 3 U/mL (final concentration) thrombin, and 5 ⁇ 10 6 cells/mL bovine subcutaneous adipose-derived stem cells
- 200 ⁇ L of the medium shown in Table 2 below was added. Two days later, the medium was replaced with each medium shown in Table 2 below, the medium was replaced every two days, and the cells were cultured until day 7 (day 9 of seeding) to prepare a three-dimensional tissue.
- FIG. 2 shows the results of strength comparison.
- the three-dimensional tissue cultured in the DMEM medium (No. 5) containing 7 types of free fatty acids the fat It was shown that the differentiation of derived stem cells was promoted.
- erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid and pristanic acid each 50 ⁇ M
- ALK5 inhibitor (2-[3-(6-methyl-2-pyridinyl)-1H-pyrazole- 4-yl]-1,5-naphthyridine, Cayman Chemical Company No. 14794) was replaced with 200 ⁇ L of DMEM medium containing 0 ⁇ M, 1 ⁇ M, 5 ⁇ M or 10 ⁇ M, the medium was changed every 2 days, and differentiation was performed for 7 days. The cells were cultured until the third day (9th day after seeding) to obtain a three-dimensional tissue.
- Each of the obtained three-dimensional tissue bodies was lipid-stained with Nile Red, and the nucleus was stained with Hoechst stain.
- the lipid staining (Nile red) fluorescence intensity was calculated relative to the nuclear staining (Hoechst) fluorescence intensity, and the fluorescence intensity was based on the three-dimensional tissue cultured in DMEM medium containing no ALK5 inhibitor. was calculated (using 3 samples for each condition).
- FIG. 3 shows a photograph of fluorescence observation of each three-dimensional tissue on day 7 of differentiation (day 9 of culture) using a confocal quantitative image cytometer CQ (Yokogawa).
- FIG. 4 shows the result of comparison of the fluorescence intensity increase rate in each three-dimensional tissue.
- the three-dimensional tissue produced in the DMEM medium containing the ALK5 inhibitor Compared to the three-dimensional tissue produced in the DMEM medium containing no ALK5 inhibitor, the three-dimensional tissue produced in the DMEM medium containing the ALK5 inhibitor, it was confirmed that adipogenesis has progressed more ( 3), and an accompanying increase in fluorescence intensity was confirmed (FIG. 4). In particular, when DMEM medium containing 5 ⁇ M or more of the ALK5 inhibitor was used, a 3-fold or more increase in fluorescence intensity was confirmed (FIG. 4). It was shown that the addition of an ALK5 inhibitor promoted the differentiation of adipose-derived stem cells into mature adipocytes.
- Production example 4 FBS-free DMEM containing fibrillated collagen component 1.2% by weight (final concentration), 6 mg/mL (final concentration) fibrinogen, 3 U/mL (final concentration) thrombin, and 5 ⁇ 10 6 cells/mL subcutaneous adipose-derived stem cells After inoculating 2 ⁇ L on a 96-well plate (manufactured by IWAKI) and incubating for 15 minutes, 200 ⁇ L of DMEM medium was added and cultured for 48 hours.
- erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid and pristanic acid each 50 ⁇ M
- ALK5 inhibitor (2-[3-(6-methyl-2-pyridinyl)-1H-pyrazole- 4-yl]-1,5-naphthyridine, Cayman Chemical Company No. 14794) was replaced with 200 ⁇ L of DMEM medium containing 5 ⁇ M), and cultured by replacing the medium every 2 days to obtain a three-dimensional tissue. .
- FIG. 5 shows a photograph of nuclei stained with Hoechst staining and fluorescence observed using a confocal quantitative image cytometer CQ (Yokogawa).
- FIG. 6 shows the rate of increase in fluorescence intensity in each three-dimensional tissue as compared with a three-dimensional tissue cultured for the same period in a DMEM medium containing no ALK5 inhibitor.
- Adipogenesis was confirmed to proceed in all three-dimensional tissue bodies on differentiation day 3, differentiation day 7, and differentiation day 14 (Fig. 5), and an accompanying increase in fluorescence intensity was confirmed. (Fig. 6).
- Fig. 5 In particular, in the three-dimensional tissues on day 7 and day 14 of culture, more adipogenesis was observed (Fig. 5), and the increase in fluorescence intensity was also remarkable (Fig. 6). There was not much difference in the rate of increase in fluorescence intensity in the three-dimensional tissue on day 7 of culture and day 14 of culture (Fig. 6).
- the cells were cultured in 200 ⁇ L of the DMEM medium described in (1) to (3) below, replacing the medium every two days.
- DMEM medium (1 ⁇ FFA) containing 50 ⁇ M each of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid and pristanic acid
- DMEM medium (2 ⁇ FFA) containing 100 ⁇ M each of myristoleic acid, phytanic acid and pristanic acid
- DMEM medium (3 ⁇ FFA) containing 50 ⁇ M each of erucic acid, elaidic acid, oleic acid, palmitoleic
- a three-dimensional tissue cultured in a DMEM medium containing erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid particularly a three-dimensional tissue cultured in a medium containing 100 ⁇ M each of the above fatty acids, It was shown that adipocytes have a high degree of maturity and that the differentiation of adipose-derived stem cells is promoted.
- FIG. 8 shows each three-dimensional tissue on day 3 of differentiation, FIG. 9 on day 7 of differentiation, and FIG. 10 on day 14 of differentiation.
- Adipogenesis was confirmed to have progressed in all three-dimensional tissues on day 3, day 7, and day 14 of differentiation (Figs. 8 to 10).
- erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid were found to promote the differentiation of adipose-derived stem cells.
- the cells were cultured in 200 ⁇ L of DMEM medium of the following (1) to (2), replacing the medium every two days.
- DMEM medium 7 FFA
- DMEM medium containing 100 ⁇ M each of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid and pristanic acid
- DMEM medium containing 100 ⁇ M each of elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid and pristanic acid
- FIG. 11 shows the results of comparison of lipid-stained (Nile Red) fluorescence intensity with respect to fluorescence intensity.
- a three-dimensional tissue cultured in a medium containing six types of fatty acids and a three-dimensional tissue cultured in a medium containing seven types of fatty acids have the same degree of adipocyte maturity, and similarly differentiate adipose-derived stem cells. was shown to be promoted.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1]
脂肪由来幹細胞を少なくとも含む細胞を、エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸、及びプリスタン酸からなる群から選択される1種以上の脂肪酸の存在下でインキュベートすることを含む、成熟脂肪細胞を含む三次元組織体の製造方法。
[2]
TGFβタイプI受容体阻害剤の存在下で上記細胞をインキュベートすることを含む、[1]に記載の製造方法。
[3]
上記TGFβタイプI受容体阻害剤の存在下でインキュベートすることが、上記TGFΒタイプI受容体阻害剤が含まれる培地中でインキュベートすることであり、培地における上記TGFβタイプI受容体阻害剤の含有量が1μM以上10μM以下である、[2]に記載の製造方法。
[4]
脂肪由来幹細胞を少なくとも含む細胞が、成熟脂肪細胞を含まない、[1]~[3]のいずれか一項に記載の方法。
[5]
上記脂肪由来幹細胞がウシ由来である、[1]~[4]のいずれか一項に記載の製造方法。
[6]
インキュベートが、96時間以上384時間以下で行われる、[1]~[5]のいずれか一項に記載の製造方法。
[7]
上記細胞を断片化細胞外マトリックス成分とともにTGFβタイプI受容体阻害剤の存在下でインキュベートすることを含む、[1]~[6]のいずれか一項に記載の製造方法。
[8]
上記三次元組織体において、上記断片化細胞外マトリックス成分が上記細胞同士の隙間に配置されている、[7]に記載の製造方法。
[9]
上記断片化細胞外マトリックス成分が断片化コラーゲン成分である、[7]又は[8]に記載の製造方法。
[10]
インキュベート前に、水性媒体中において上記細胞と上記断片化細胞外マトリックス成分とを接触させる工程をさらに含む、[7]~[9]のいずれか一項に記載の製造方法。
[11]
脂肪由来幹細胞を少なくとも含む細胞をエルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸、及び、プリスタン酸からなる群から選択される1種以上の脂肪酸の存在下でインキュベートすることを含む、脂肪由来幹細胞の分化促進方法。
[12]
TGFβタイプI受容体阻害剤の存在下で上記細胞をインキュベートすることを含む、[11]に記載の方法。
[13]
上記TGFβタイプI受容体阻害剤の存在下でインキュベートすることが、上記TGFβタイプI受容体阻害剤が含まれる培地中でインキュベートすることであり、培地における上記TGFβタイプI受容体阻害剤の含有量が1μM以上10μM以下である、[12]に記載の方法。
[14]
上記脂肪由来幹細胞がウシ由来である、[11]~[13]のいずれか一項に記載の方法。
[15]
インキュベートが、96時間以上384時間以下で行われる、[11]~[14]のいずれか一項に記載の方法。
[16]
脂肪由来幹細胞を少なくとも含む細胞を断片化細胞外マトリックス成分とともにTGFβタイプI受容体阻害剤の存在下でインキュベートすることを含む、[11]~[15]のいずれか一項に記載の方法。
[17]
上記断片化細胞外マトリックス成分が断片化コラーゲン成分である、[16]に記載の方法。
[18]
インキュベート前に、水性媒体中において上記細胞と上記断片化細胞外マトリックス成分とを接触させる工程をさらに含む、[16]又は[17]に記載の方法。
[P1]
脂肪由来幹細胞を少なくとも含む細胞をTGFβタイプI受容体阻害剤の存在下でインキュベートすることを含む、成熟脂肪細胞を含む三次元組織体の製造方法。
[P2]
エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸、及び、プリスタン酸からなる群から選択される1種以上の脂肪酸の存在下で上記細胞をインキュベートすることを含む、[P1]に記載の製造方法。
[P3]
脂肪由来幹細胞を少なくとも含む細胞が、成熟脂肪細胞を含まない、[P1]又は[P2]に記載の方法。
[P4]
上記TGFβタイプI受容体阻害剤の存在下でインキュベートすることが、上記TGFβタイプI受容体阻害剤が含まれる培地中でインキュベートすることであり、培地における上記TGFβタイプI受容体阻害剤の含有量が1μM以上10μM以下である、[P1]~[P3]のいずれかに記載の製造方法。
[P5]
上記脂肪由来幹細胞がウシ由来である、[P1]~[P4]のいずれかに記載の製造方法。
[P6]
インキュベートが、96時間以上384時間以下で行われる、[P1]~[P5]のいずれかに記載の製造方法。
[P7]
上記細胞を断片化細胞外マトリックス成分とともにTGFβタイプI受容体阻害剤の存在下でインキュベートすることを含む、[P1]~[P6]のいずれかに記載の製造方法。
[P8]
上記三次元組織体において、上記断片化細胞外マトリックス成分が上記細胞同士の隙間に配置されている、[P7]に記載の製造方法。
[P9]
上記断片化細胞外マトリックス成分が断片化コラーゲン成分である、[P7]又は[P8]に記載の製造方法。
[P10]
インキュベート前に、水性媒体中において上記細胞と上記断片化細胞外マトリックス成分とを接触させる工程をさらに含む、[P7]~[P9]のいずれかに記載の製造方法。
[P11]
脂肪由来幹細胞を少なくとも含む細胞をTGFβタイプI受容体阻害剤の存在下でインキュベートすることを含む、脂肪由来幹細胞の分化促進方法。
[P12]
上記TGFβタイプI受容体阻害剤の存在下でインキュベートすることが、上記TGFβタイプI受容体阻害剤が含まれる培地中でインキュベートすることであり、培地における上記TGFβタイプI受容体阻害剤の含有量が1μM以上10μM以下である、[P11]に記載の方法。
[P13]
上記脂肪由来幹細胞がウシ由来である、[P11]又は[P12]に記載の方法。
[P14]
インキュベートが、96時間以上384時間以下で行われる、[P11]~[P13]のいずれかに記載の方法。
[P15]
脂肪由来幹細胞を少なくとも含む細胞を断片化細胞外マトリックス成分とともにTGFβタイプI受容体阻害剤の存在下でインキュベートすることを含む、[P11]~[P14]のいずれかに記載の方法。
[P16]
上記断片化細胞外マトリックス成分が断片化コラーゲン成分である、[P15]に記載の方法。
[P17]
インキュベート前に、水性媒体中において上記細胞と上記断片化細胞外マトリックス成分とを接触させる工程をさらに含む、[P15]又は[P16]に記載の方法。
[P18]
脂肪由来幹細胞を少なくとも含む細胞を、エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸、及びプリスタン酸の存在下でインキュベートすることを含む、脂肪由来幹細胞の分化促進方法。
[P19]
上記脂肪由来幹細胞がウシ由来である、[P18]に記載の方法。
[P20]
インキュベートが、96時間以上384時間以下で行われる、[P18]又は[P19]に記載の方法。
[P21]
脂肪由来幹細胞を少なくとも含む細胞を、断片化細胞外マトリックス成分とともに、エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸、及びプリスタン酸の存在下でインキュベートすることを含む、[P18]~[P20]のいずれかに記載の方法。
[P22]
上記断片化細胞外マトリックス成分が断片化コラーゲン成分である、[P21]に記載の方法。
[P23]
インキュベート前に、水性媒体中において上記細胞と上記断片化細胞外マトリックス成分とを接触させる工程をさらに含む、[P21]又は[P22]に記載の方法。
凍結乾燥処理を行った三次元組織体の全量を6mol/L HClと混合し、ヒートブロックで95℃、20時間以上インキュベートした後、室温に戻す。13000gで10分遠心分離した後、サンプル溶液の上澄みを回収する。後述する測定において結果が検量線の範囲内に収まるように6mol/L HClで適宜希釈した後、200μLを100μLの超純水で希釈することでサンプルを調製する。サンプルは35μL用いる。
スクリューキャップチューブに125μLのスタンダード溶液(1200μg/mL in acetic acid)と、125μLの12mol/l HClを加え混合し、ヒートブロックで95℃、20時間インキュベートした後、室温に戻す。13000gで10分遠心分離した後、上澄みを超純水で希釈して300μg/mLのS1を作製し、S1を段階的に希釈してS2(200μg/mL)、S3(100μg/mL)、S4(50μg/mL)、S5(25μg/mL)、S6(12.5μg/mL)、S7(6.25μg/mL)を作製する。4mol/l HCl90μLのみのS8(0μg/mL)も準備する。
35μLのスタンダード及びサンプルをそれぞれプレート(QuickZyme Total Collagen Assayキット付属、QuickZyme Biosciences社)に加える。75μLのアッセイバッファ(上記キット付属)をそれぞれのウェルに加える。シールでプレートを閉じ、20分シェイキングしながら室温でインキュベートする。シールをはがし、75μLのdetection reagent (reagent A:B=30μL:45μL、上記キット付属)をそれぞれのウェルに加える。シールでプレートを閉じ、シェイキングで溶液を混合し、60℃で60分インキュベートする。氷上で十分に冷まし、シールをはがして570nmの吸光度を測定する。サンプルの吸光度をスタンダードと比較することでコラーゲン成分量を算出する。
(細胞及びコラーゲン)
・FBS(Thermo Fisher社、Gibco)
・皮下脂肪由来幹細胞(ADSC、ウシ由来、食肉用牛肉より常法により採取)
・エルカ酸(シグマ社 #E3385)
・エライジン酸(シグマ社 #E4637)
・オレイン酸(シグマ社 #O1008)
・パルミトレイン酸(シグマ社 #P9417)
・ミリストレイン酸(シグマ社 #M3525)
・フィタン酸(シグマ社 #P4060、又はラローダ ファイン ケミカルズ社 11-1600)
・プリスタン酸(シグマ社 #P6617、又はラローダ ファイン ケミカルズ社 11-1500)
・ウシ血漿由来フィブリノゲンI-S型(シグマ社 #F8630)
・DMEM培地(高グルコース、ナカライテスク社):以下、単にDMEMと記載した場合、FBSを10%含むものを指すものとする。
・50mg/mL フィブリノゲンストック溶液:フィブリノゲン 50mgをエッペンドルフチューブに秤とり、DMEM(0%FBS、1%抗生物質)1mLをすぐに加える。手動でチューブを振って混合した後、37℃のウォーターバスに3~5分間置き、孔径0.2μmのフィルターでろ過し、エッペンドルフチューブに等量分注したものを使用。
製造例1
得られた解繊コラーゲン成分1.2重量%(最終濃度)、6mg/mL(最終濃度)フィブリノゲン、3U/mL(最終濃度)トロンビン、及び5×106cells/mLのウシ皮下脂肪由来幹細胞を含むFBS非含有DMEM 2μLを、96ウェルマイクロプレート(IWAKI社製)上に播種し、15分間インキュベートした。15分後に200μLのDMEM培地を加えた。
解繊コラーゲン成分1.2重量%(最終濃度)、6mg/mL(最終濃度)フィブリノゲン、3U/mL(最終濃度)トロンビン、及び5×106cells/mLのウシ皮下脂肪由来幹細胞を含むFBS非含有DMEM 2μLを、96ウェルプレート(IWAKI社製)上に播種し15分インキュベートした後、以下の表2に示される培地を200μL加えた。その2日後に、下記表2に示す各培地で培地交換し、2日ごとに培地を交換し、7日目(播種9日目)まで培養して三次元組織体を作製した。
解繊コラーゲン成分1.2重量%(最終濃度)、6mg/mL(最終濃度)フィブリノゲン、3U/mL(最終濃度)トロンビン、及び5×106cells/mLの皮下脂肪由来幹細胞を含むFBS非含有DMEM 2μLを、96ウェルプレート(IWAKI社製)上に播種し15分インキュベートした後、DMEM培地を200μL加え、48時間培養した。その後、エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸及びプリスタン酸各50μMと、ALK5阻害剤(2-[3-(6-メチル-2-ピリジニル)-1H-ピラゾール-4-イル]-1,5-ナフチリジン、Cayman Chemical社 No. 14794)を0μM、1μM、5μM又は10μMを含有するDMEM培地200μLで培地交換を行い、2日ごとに培地を交換し、分化7日目(播種から9日目)まで培養し、三次元組織体を得た。
解繊コラーゲン成分1.2重量%(最終濃度)、6mg/mL(最終濃度)フィブリノゲン、3U/mL(最終濃度)トロンビン、5×106cells/mLの皮下脂肪由来幹細胞を含むFBS非含有DMEM 2μLを、96ウェルプレート(IWAKI社製)上に播種し15分インキュベートした後、DMEM培地200μLを加えて48時間培養した。その後、エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸及びプリスタン酸各50μMと、ALK5阻害剤(2-[3-(6-メチル-2-ピリジニル)-1H-ピラゾール-4-イル]-1,5-ナフチリジン、Cayman Chemical社 No. 14794)を5μM含有するDMEM培地200μLで培地交換を行い、2日ごとに培地を交換して培養し、三次元組織体を得た。
解繊コラーゲン成分1.2重量%(最終濃度)、6mg/mL(最終濃度)フィブリノゲン、3U/mL(最終濃度)トロンビン、及び5×106cells/mLのウシ皮下脂肪由来幹細胞を含むFBS非含有DMEM 2μLを96ウェルマイクロプレートに播種し15分インキュベート、その後DMEM培地を加え48時間培養することで三次元組織体を得た。
(1)エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸及びプリスタン酸各50μMを含むDMEM培地(1×FFA)、(2)エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸及びプリスタン酸各100μMを含むDMEM培地(2×FFA)、(3)エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸及びプリスタン酸各150μMを含むDMEM培地(3×FFA)
解繊コラーゲン成分1.2重量%(最終濃度)、6mg/mL(最終濃度)フィブリノゲン、3U/mL(最終濃度)トロンビン、及び5×106cells/mLのウシ皮下脂肪由来幹細胞を含むFBS非含有DMEM 2μLを96ウェルマイクロプレートに播種し15分インキュベート、その後DMEM培地を加え48時間培養することで三次元組織体を得た。
(1)エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸及びプリスタン酸各100μMを含むDMEM培地(7 FFA)、
(2)エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸及びプリスタン酸各100μMを含むDMEM培地(6 FFA)
Claims (18)
- 脂肪由来幹細胞を少なくとも含む細胞を、エルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸、及び、プリスタン酸からなる群から選択される1種以上の脂肪酸の存在下でインキュベートすることを含む、成熟脂肪細胞を含む三次元組織体の製造方法。
- TGFβタイプI受容体阻害剤の存在下で前記細胞をインキュベートすることを含む、請求項1に記載の製造方法。
- 前記TGFβタイプI受容体阻害剤の存在下でインキュベートすることが、前記TGFΒタイプI受容体阻害剤が含まれる培地中でインキュベートすることであり、培地における前記TGFβタイプI受容体阻害剤の含有量が1μM以上10μM以下である、請求項2に記載の製造方法。
- 脂肪由来幹細胞を少なくとも含む細胞が、成熟脂肪細胞を含まない、請求項1~3のいずれか一項に記載の方法。
- 前記脂肪由来幹細胞がウシ由来である、請求項1~4のいずれか一項に記載の製造方法。
- インキュベートが、96時間以上384時間以下で行われる、請求項1~5のいずれか一項に記載の製造方法。
- 前記細胞を断片化細胞外マトリックス成分とともにTGFβタイプI受容体阻害剤の存在下でインキュベートすることを含む、請求項1~6のいずれか一項に記載の製造方法。
- 前記三次元組織体において、前記断片化細胞外マトリックス成分が前記細胞同士の隙間に配置されている、請求項7に記載の製造方法。
- 前記断片化細胞外マトリックス成分が断片化コラーゲン成分である、請求項7又は8に記載の製造方法。
- インキュベート前に、水性媒体中において前記細胞と前記断片化細胞外マトリックス成分とを接触させる工程をさらに含む、請求項7~9のいずれか一項に記載の製造方法。
- 脂肪由来幹細胞を少なくとも含む細胞をエルカ酸、エライジン酸、オレイン酸、パルミトレイン酸、ミリストレイン酸、フィタン酸、及び、プリスタン酸からなる群から選択される1種以上の脂肪酸の存在下でインキュベートすることを含む、脂肪由来幹細胞の分化促進方法。
- TGFβタイプI受容体阻害剤の存在下で前記細胞をインキュベートすることを含む、請求項11に記載の方法。
- 前記TGFβタイプI受容体阻害剤の存在下でインキュベートすることが、前記TGFβタイプI受容体阻害剤が含まれる培地中でインキュベートすることであり、培地における前記TGFβタイプI受容体阻害剤の含有量が1μM以上10μM以下である、請求項12に記載の方法。
- 前記脂肪由来幹細胞がウシ由来である、請求項11~13のいずれか一項に記載の方法。
- インキュベートが、96時間以上384時間以下で行われる、請求項11~14のいずれか一項に記載の方法。
- 脂肪由来幹細胞を少なくとも含む細胞を断片化細胞外マトリックス成分とともにTGFβタイプI受容体阻害剤の存在下でインキュベートすることを含む、請求項11~15のいずれか一項に記載の方法。
- 前記断片化細胞外マトリックス成分が断片化コラーゲン成分である、請求項16に記載の方法。
- インキュベート前に、水性媒体中において前記細胞と前記断片化細胞外マトリックス成分とを接触させる工程をさらに含む、請求項16又は17に記載の方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/276,912 US20240117313A1 (en) | 2021-02-15 | 2022-02-15 | Method for producing three-dimensional tissue body and method for promoting differentiation of adipose-derived stem cells |
CN202280013867.3A CN116867892A (zh) | 2021-02-15 | 2022-02-15 | 三维组织体的制造方法和脂肪来源干细胞的分化促进方法 |
EP22752880.9A EP4293106A4 (en) | 2021-02-15 | 2022-02-15 | METHOD FOR PRODUCING A THREE-DIMENSIONAL TISSUE BODY AND METHOD FOR PROMOTING THE DIFFERENTIATION OF STEM CELLS DERIVED FROM ADIPOSE TISSUE |
JP2022580721A JPWO2022173058A1 (ja) | 2021-02-15 | 2022-02-15 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-021791 | 2021-02-15 | ||
JP2021021791 | 2021-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022173058A1 true WO2022173058A1 (ja) | 2022-08-18 |
Family
ID=82838393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/005969 WO2022173058A1 (ja) | 2021-02-15 | 2022-02-15 | 三次元組織体の製造方法及び脂肪由来幹細胞の分化促進方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240117313A1 (ja) |
EP (1) | EP4293106A4 (ja) |
JP (1) | JPWO2022173058A1 (ja) |
CN (1) | CN116867892A (ja) |
WO (1) | WO2022173058A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015072164A1 (ja) | 2013-11-14 | 2015-05-21 | 国立大学法人大阪大学 | コラーゲンを含む被膜でコートされた細胞及びその製造方法 |
WO2017069222A1 (ja) * | 2015-10-21 | 2017-04-27 | 京都府公立大学法人 | 細胞の調製方法 |
WO2017146124A1 (ja) | 2016-02-22 | 2017-08-31 | 国立大学法人大阪大学 | 立体的細胞組織の製造方法 |
WO2018143286A1 (ja) | 2017-01-31 | 2018-08-09 | 凸版印刷株式会社 | 三次元組織体及びその製造方法、並びに、三次元組織体の形成剤 |
JP2020505038A (ja) * | 2017-01-23 | 2020-02-20 | ステムセル テクノロジーズ カナダ インコーポレイテッド | 幹細胞の生存および増殖を高めるための培地および方法 |
WO2020203369A1 (ja) * | 2019-04-01 | 2020-10-08 | 凸版印刷株式会社 | 細胞構造体及び細胞構造体の製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080038236A1 (en) * | 2006-03-06 | 2008-02-14 | Artecel Sciences, Inc. | Biocompatible scaffolds and adipose-derived stem cells |
EP3634152A1 (en) * | 2017-06-07 | 2020-04-15 | Wild Type, Inc. | Ex vivo meat production |
-
2022
- 2022-02-15 CN CN202280013867.3A patent/CN116867892A/zh active Pending
- 2022-02-15 JP JP2022580721A patent/JPWO2022173058A1/ja active Pending
- 2022-02-15 EP EP22752880.9A patent/EP4293106A4/en active Pending
- 2022-02-15 US US18/276,912 patent/US20240117313A1/en active Pending
- 2022-02-15 WO PCT/JP2022/005969 patent/WO2022173058A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015072164A1 (ja) | 2013-11-14 | 2015-05-21 | 国立大学法人大阪大学 | コラーゲンを含む被膜でコートされた細胞及びその製造方法 |
WO2017069222A1 (ja) * | 2015-10-21 | 2017-04-27 | 京都府公立大学法人 | 細胞の調製方法 |
WO2017146124A1 (ja) | 2016-02-22 | 2017-08-31 | 国立大学法人大阪大学 | 立体的細胞組織の製造方法 |
JP2020505038A (ja) * | 2017-01-23 | 2020-02-20 | ステムセル テクノロジーズ カナダ インコーポレイテッド | 幹細胞の生存および増殖を高めるための培地および方法 |
WO2018143286A1 (ja) | 2017-01-31 | 2018-08-09 | 凸版印刷株式会社 | 三次元組織体及びその製造方法、並びに、三次元組織体の形成剤 |
WO2020203369A1 (ja) * | 2019-04-01 | 2020-10-08 | 凸版印刷株式会社 | 細胞構造体及び細胞構造体の製造方法 |
Non-Patent Citations (3)
Title |
---|
See also references of EP4293106A4 |
TURNER PAUL A.; GURUMURTHY BHUVANESWARI; BAILEY JENNIFER L.; ELKS CARRIE M.; JANORKAR AMOL V.: "Adipogenic differentiation of human adipose-derived stem cells grown as spheroids", PROCESS BIOCHEMISTRY, vol. 59, 1 August 2017 (2017-08-01), GB , pages 312 - 320, XP085197573, ISSN: 1359-5113, DOI: 10.1016/j.procbio.2017.02.003 * |
ZENG RUIXIA, FANG YAN, ZHANG YIBO, BAI SHULING: "p62 is linked to mitophagy in oleic acid-induced adipogenesis in human adipose-derived stromal cells", LIPIDS IN HEALTH AND DISEASE, vol. 17, no. 1, 1 December 2018 (2018-12-01), pages 1 - 10, XP055959054, DOI: 10.1186/s12944-018-0733-5 * |
Also Published As
Publication number | Publication date |
---|---|
EP4293106A4 (en) | 2024-07-31 |
US20240117313A1 (en) | 2024-04-11 |
CN116867892A (zh) | 2023-10-10 |
JPWO2022173058A1 (ja) | 2022-08-18 |
EP4293106A1 (en) | 2023-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020203369A1 (ja) | 細胞構造体及び細胞構造体の製造方法 | |
JP7201972B2 (ja) | 三次元組織体及びその製造方法並びに細胞含有組成物の製造方法 | |
WO2021100709A1 (ja) | 細胞構造体及びその製造方法並びに被験物質の肝毒性の評価方法 | |
JP6903299B2 (ja) | 細胞外マトリックス含有組成物及びその製造方法、並びに三次元組織体、三次元組織体形成剤 | |
US20210115377A1 (en) | Extracellular-matrix-containing composition, temporary scaffold for three-dimensional tissue formation, three-dimensional tissue formation agent, and method for recovering cells from three-dimensional tissue | |
WO2021177407A1 (ja) | 三次元組織体のヤング率を制御する方法、三次元組織体の製造方法、及び三次元組織体 | |
WO2022173058A1 (ja) | 三次元組織体の製造方法及び脂肪由来幹細胞の分化促進方法 | |
WO2022113540A1 (ja) | 組織体の製造方法、及び脂肪由来幹細胞の分化促進方法 | |
WO2023074814A1 (ja) | 組織体の製造方法及びヒト由来の脂肪由来幹細胞の血管内皮細胞への分化促進方法 | |
JP6797389B1 (ja) | 細胞外マトリックス含有組成物及びその製造方法、並びに三次元組織体及びその製造方法 | |
WO2022091822A1 (ja) | 細胞構造体の凍結方法 | |
JP7526397B2 (ja) | 細胞構造体及びその製造方法 | |
WO2021054079A1 (ja) | 細胞構造体及びその製造方法 | |
JP2022036357A (ja) | 細胞構造体及び細胞構造体の製造方法 | |
CN114931670A (zh) | 活性物质及其自愈合水凝胶在修复软骨中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22752880 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022580721 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280013867.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18276912 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022752880 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022752880 Country of ref document: EP Effective date: 20230915 |